Kalaris Therapeutics (KLRS) Q3 2025 earnings summary

Executive summary

• Focused on developing TH103, a novel anti-VEGF drug for retinal diseases, with ongoing Phase 1a and 1b/2 clinical trials in neovascular AMD and plans to expand into DME and RVO.

• Initiated enrollment for Phase 1b/2 multiple ascending dose trial of TH103 in nAMD; Phase 1a single ascending dose trial remains on track for initial data by year end 2025.

• No products approved or revenue generated; operations funded by equity, convertible notes, and $102.1M in cash from a merger with AlloVir.

• Merger with AlloVir in March 2025 resulted in a reverse recapitalization, with Legacy Kalaris shareholders owning 74.47% of the combined company.

• Entered agreement with KBI Biopharma for clinical supply manufacturing; opened new headquarters and hired a new CFO.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $77.0M as of September 30, 2025, up from $1.6M at December 31, 2024, primarily due to the merger with AlloVir.

• Net loss for Q3 2025 was $11.9M, compared to $38.1M in Q3 2024; net loss for the nine months ended September 30, 2025 was $33.4M, down from $47.1M in the prior year period.

• Research and development expenses for the nine months ended September 30, 2025 were $23.6M, down from $41.2M year-over-year, primarily due to a $32.1M one-time royalty obligation expense in 2024.

• General and administrative expenses increased to $11.8M for the nine months ended September 30, 2025, up from $3.4M year-over-year, mainly due to higher legal, accounting, insurance, and personnel costs post-merger.

• No revenue recognized; all funding from financing activities.

Outlook and guidance

• Cash runway expected to fund operations into 2027 based on current plans.

• Initial clinical data from the Phase 1a trial of TH103 expected by year-end 2025; Phase 1b/2 data expected in the second half of 2026.

• Anticipates continued operating losses and need for additional capital to advance development and commercialization.